Boston Scientific Corporation (ETR:BSX)
Market Cap | 135.74B |
Revenue (ttm) | 16.24B |
Net Income (ttm) | 1.88B |
Shares Out | n/a |
EPS (ttm) | 1.27 |
PE Ratio | 72.20 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | n/a |
Average Volume | 229 |
Open | 90.80 |
Previous Close | 90.60 |
Day's Range | 90.80 - 90.80 |
52-Week Range | 62.00 - 105.00 |
Beta | n/a |
RSI | 54.38 |
Earnings Date | Apr 23, 2025 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial numbers in USD Financial StatementsNews

$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 8.98% on an annualized basis producing an average annual return of 20.36%. Currently, Boston Scientific has a marke...

Boston Scientific announces upcoming investor conference schedule
MARLBOROUGH, Mass. , May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.

Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ann...

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results
Boston Scientific Corporation (NYSE: BSX) posted better-than-expected earnings for the first quarter on Wednesday . The company reported first-quarter 2025 revenues of $4.66 billion, beating the cons...

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results
Boston Scientific Corporation BSX posted better-than-expected earnings for the first quarter on Wednesday.
IBD Stock Of The Day, Boston Scientific, A 'Top Decile' Player, Is Eyeing Two Entries
Boston Scientific is Thursday's IBD Stock Of The Day. Shares are forming a double-bottom base, while approaching an early entry.
Boston scientific raises full-year 2025 guidance with 12%-14% organic growth projection
Boston Scientific Corporation (BSX) Q1 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ETCompany ParticipantsJon Monson - Senior Vice President,...

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition
Boston Scientific Corporation (NYSE: BSX) on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion . Sales increased 20.9% on a reported bas...

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition
Boston Scientific Corporation BSX on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2211161240-988963093b4c4028b952299234eed592.jpg)
Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire
Shares of Boston Scientific rose sharply Wednesday after the firm posted better-than-expected quarterly results.
Boston Scientific Stock Jets 8% Higher On Solid Quarterly Beat, Hiked Guidance
Boston Scientific stock jumped Wednesday after the medtech company beat first-quarter expectations and hiked its sales outlook.

Boston Scientific raises 2025 profit forecast on strong heart device sales
Boston Scientific raised its annual profit forecast after strong sales of its heart devices helped beat Wall Street expectations for first-quarter profit.
Boston Scientific CFO Dan Brennan to retire, Monson to succeed

Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan
MARLBOROUGH, Mass. , April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to ret...
Boston Scientific Non-GAAP EPS of $0.75 beats by $0.08, revenue of $4.66B beats by $90M

Boston Scientific announces results for first quarter 2025
MARLBOROUGH, Mass. , April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported...
Earnings Scheduled For April 23, 2025
Companies Reporting Before The Bell • GATX (NYSE: GATX) is estimated to report quarterly earnings at $2.09 per share on revenue of $417.09 million. • First Hawaiian (NASDAQ: FHB) is expected to repo...
Boston Scientific Q1 2025 Earnings Preview

Earnings Preview: Boston Scientific
Boston Scientific (NYSE: BSX) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

Stryker, Boston Scientific down as new tariffs impact medtech industry
New US tariffs could disrupt the medtech industry, impacting major companies like Boston Scientific and Stryker. Read more here.

Price Over Earnings Overview: Boston Scientific
Looking into the current session, Boston Scientific Inc. (NYSE: BSX) shares are trading at $96.89, after a 3.16% drop. Over the past month, the stock fell by 1.95% , but over the past year, it actual...

Goldman Sachs Thinks These Stocks Are ‘Insulated' From a Trade War
Amdocs, Kroger, Bank of New York Mellon and Valvoline lead a list of stocks that Goldman Sachs calls “insensitive” to market volatility.

Boston Scientific announces conference call discussing first quarter 2025 results
MARLBOROUGH, Mass. , April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter...